{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"QTcF: >=450 to <480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"QTcF: >=480 to <500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"QTcF: >=500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"QTcF: Increase from baseline >=30 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"QTcF: Increase from baseline >=60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"QTcB: >=450 to <480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"QTcB: >=480 to <500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"QTcB: >=500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"}]}],"title":"QTcB: Increase from baseline >=30 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"QTcB: Increase from baseline >=60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"QT: >=450 to <480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"QT: >=480 to <500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"QT: >=500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"title":"QT: Increase from baseline >=30 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"QT: Increase from baseline >=60 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"ECG abnormalities criteria included: 1) QTc interval adjusted according to Bazett formula (QTcF) in millisecond (msec): greater than equal to (\\>=) 450 to less than (\\<) 480, \\>=480 to \\<500, \\>=500, increase from baseline \\>=30, increase from baseline \\>=60; 2) QTc interval adjusted according to Fridericia formula (QTcB) (msec): \\>=450 to \\<480, \\>=480 to \\<500, \\>=500, increase from baseline \\>=30, increase from baseline \\>=60. 3) QT (msec): \\>=450 to \\<480, \\>=480 to \\<500, \\>=500, increase from baseline \\>=30, increase from baseline \\>=60.","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment and had at least 1 post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)","title":"Number of Participants With Electrocardiogram (ECG) Abnormalities","type":"SECONDARY","unitOfMeasure":"Participants"}